MSD
MSD chooses partner to develop ‘game-changing’ cancer therapies
January 6, 2016Research and Development CPABs, Cancer, Cell-Penetrating Alphabodies, Complix, MSD, autoimmune diseases
MSD has entered a research collaboration with biopharma company Complix, using the company’s proprietary technology to develop new treatments for …
WHO to review MSD’s Ebola vaccine for emergency use
December 24, 2015Manufacturing and Production, Research and Development Ebola vaccine, Ebola virus, MSD, WHO, Zebov
The World Health Organisation (WHO) has accepted MSD’s application for the company’s investigational Ebola vaccine, V920 (Zebov), to be reviewed …
MSD’s Keytruda impresses in lung cancer chemotherapy trial
December 21, 2015Manufacturing and Production, Research and Development MSD, PD-L1, docetaxel, keytruda, lung cancer, non small cell lung cancer, non-small cell lung cancer, pd-1, pembrolizumab
MSD’s Keytruda significantly improved overall survival (OS) compared to chemotherapy in people with lung cancer and PD-L1 expression, a trial …
MSD UK appoints Jessica Fine as executive director of external affairs
December 16, 2015Medical Communications Jessica Fine, MSD
MSD has appointed former Lexington Health boss Jessica Fine to lead its external affairs team in the UK from April …
MSD’s Keytruda shows promise in multiple myeloma
December 7, 2015Manufacturing and Production MSD, Revlimid, dexamethasone, keytruda, multiple myeloma, pembrolizumab
MSD has announced that it has initiated two Phase III studies based in part on the strength of early data, …
Sales up at MSD while Keytruda hits survival target in late-stage trial
October 28, 2015Research and Development, Sales and Marketing MSD, Merck, financial results, keytruda, pembrolizumab
Worldwide sales at MSD were $10.1 billion in the third quarter of 2015, a 4% increase after accounting for the …
NICE issues draft guidance for MSD’s Ezetrol
October 21, 2015Sales and Marketing MSD, NICE, cardiovascular disease, ezetimibie, ezetrol, high cholesterol
NICE has published draft guidance recommending MSD’s Ezetrol as an option for some adults with high cholesterol. The guidance updates …
MSD’s Keytruda receives green light from NICE for NHS use
October 12, 2015Sales and Marketing MSD, Merck, NICE, keytruda, melanoma, pembrolizumab, skin cancer
The UK healthcare watchdog NICE has recommended Keytruda as a treatment for advanced skin cancer – its second endorsement of …
Merck and Wayra to tackle NHS funding gap with startup rewards programme
September 25, 2015Research and Development MSD, Merck
Merck Sharpe and Dohme (MSD) and Wayra Open Future, Telefonica’s digital start up accelerator, are investing in digital innovation in …
David Khougazian announced as president of Sanofi Pasteur MSD
July 29, 2015Business Services, Research and Development, Sales and Marketing MSD, Merck, Sanofi Pasteur
Sanofi Pasteur and Merck have appointed David Khougazian as president of their joint company, Sanofi Pasteur MSD. David Khougazian joined …
Merck launches new antibiotic in the UK
June 5, 2015Research and Development, Sales and Marketing AMR, Antibiotics, MSD, Merck, Sivextro, antimicrobial resistance, cubist, tedizolid phosphate
Merck has launched the first new drug in a class of antibiotics in the UK in almost 15 years, becoming …
Hospira launches biosimilar monoclonal antibody
February 16, 2015Research and Development, Sales and Marketing MSD, Merck, Remicade, biosimilar. hospira, inflectra, infliximab
Hospira has won the race to become the first company to launch a biosimilar version of an anti-TNF biologic, after …
Novartis hires Merck president to lead oncology
June 3, 2014Medical Communications, Research and Development, Sales and Marketing Bruno Strigini, MSD, Merck, Novartis, oncology
Novartis has hired Merck’s president of Europe and Canada Bruno Strigini to be its president of oncology. The role was …
Endocyte lung cancer drug shows promise
March 24, 2014Research and Development, Sales and Marketing Endocyte, MSD, NSCLC, lung cancer, vintafolide
Endocyte and partner MSD have released positive mid-stage trial results for their investigational lung cancer drug vintafolide. The treatment met …
Mike Nally replaces Deepak Khanna as MSD head
December 11, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Deepak Khanna, MSD, mike nally
Merck Sharp & Dohme has confirmed that Mike Nally will succeed Deepak Khanna as managing director for MSD in the …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
